Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
A phase 3 trial of Magrolimab and Azacitidine in Myelodysplastic syndromes / neoplasms, run by Gilead Sciences, recorded as terminated on the registry.
Overview
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) is a phase 3 interventional study registered as NCT04313881 by Gilead Sciences, with 539 participants recorded, started 2020-09-09 and due to reach its primary completion in 2023-09-13. Interventions recorded: Magrolimab, Azacitidine, Placebo. Conditions recorded: Myelodysplastic Syndromes.
Linked to the drug Magrolimab because the registry names it among its interventions and Myelodysplastic syndromes / neoplasms among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
Shares Magrolimab, Gilead Sciences (incl. Kite), Azacitidine and the tag pipeline.
- TrialStudy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
Shares Magrolimab, Gilead Sciences (incl. Kite), Azacitidine and the tag pipeline.
- TrialPBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialStudy to Evaluate the Safety and Tolerability of EP0042
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialA Study of BGB-11417 in Participants With Myeloid Malignancies
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialA Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialA Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
- TrialClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.